HK1 and neoplasm: These results were further confirmed by the changes in protein levels of SLC2A3 and PGAM1, and HK1, as therapeutic targets of 2‐DG and 3‐BP (Pajak et al, 2019), by western blot analysis from tumor tissues (Fig 5N).